question,correct_answer,model_output,extracted_info,correct,urls
"Find/search the clinical trial id that best describes the efficacy of Tasquinimod monotherapy compared to Placebo when used to treat Prostate cancer.
Output it in the format NCT<Number>",NCT01234311,"The clinical trial that best describes the efficacy of tasquinimod monotherapy compared to placebo in treating prostate cancer is identified by the ClinicalTrials.gov identifier NCT01234311. This is a Phase II randomized, double-blind, placebo-controlled study conducted to evaluate the activity of tasquinimod in men with minimally symptomatic metastatic castration-resistant prostate cancer. The study found that tasquinimod significantly improved progression-free survival compared to placebo. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21931019/?utm_source=openai)) ",NCT01234311,True,
"Find/search the clinical trial id that best describes the efficacy of Panitumumab monotherapy compared to Best supportive care when used to treat Colorectal cancer (Metastatic).
Output it in the format NCT<Number>",NCT00113763,"The clinical trial that best describes the efficacy of panitumumab monotherapy compared to best supportive care in treating metastatic colorectal cancer is identified by the ClinicalTrials.gov identifier NCT00339183. This open-label phase III trial, published in May 2007, evaluated the use of panitumumab plus best supportive care versus best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Panitumumab?utm_source=openai)) ",NCT00339183,False,
"Find/search the clinical trial id that best describes the efficacy of Capecitabine monotherapy compared to Observation when used to treat Nasopharyngeal carcinoma.
Output it in the format NCT<Number>",NCT02958111,"I couldn't locate a specific clinical trial ID comparing the efficacy of capecitabine monotherapy to observation in treating nasopharyngeal carcinoma. However, a clinical trial titled ""A Study of Capecitabine in Patients With Nasopharyngeal Carcinoma"" (NCT00475504) investigated the use of capecitabine in patients with nasopharyngeal carcinoma. While this study did not directly compare capecitabine to observation, it may provide valuable insights into the treatment's efficacy. ",NCT00475504,False,
